Collagen-based implant materials with central agent depot for the therapy of bone defects

用于骨缺损治疗的具有中央药剂库的胶原基植入材料

• 批准号: 451966134
• 负责人: Professor Dr. Michael Gelinsky
• 金额: --
• 依托单位: Zentrum für Translationale Knochen-, Gelenk- und Weichgewebeforschung
• 依托单位国家: 德国
• 项目类别: Research Grants (Transfer Project)
• 资助国家: 德国
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/451966134?language=en
• 关键词: Collagen; based; implant; materials; central

The concept of in situ tissue engineering (TE) could open up new treatment options, e.g. for extensive or non-healing bone defects. In contrast to the classic TE, no cells are implanted, so that the costs and the approval effort for such implants are lower. The present transfer project builds on the work of sub-project M4 (Establishment of the new approach `in situ tissue engineering΄ for bone defect healing) of the completed SFB/Transregio 79 and is to further develop the concept investigated there with an application partner for use in the clinic. At the end of TR79, a biomimetic bone substitute material made of mineralized collagen has been developed, which is loaded with chemoattractive substances in a central depot. It could be shown that the concentration gradient established in an aqueous environment stimulates the migration of mesenchymal stem cells and endothelial cells into the scaffold and thus promotes defect healing compared to unmodified scaffolds.The focus of the transfer project is now (1) the transfer of scaffold production to clinically approved, equine collagen and the development of an industrially feasible process chain, (2) the investigation of alternative depot components for controlled drug release with the aim of expanding the range of applications of the drug-containing implants, (3) the exploration of new, suitable strategies for the introduction of the drug depot, (4) the study of the sterilisability and shelf life of implants containing the drug deposit, (5) the standardization of the production of chemoattractive drug mixtures from hypoxia-conditioned medium and (6) the testing of the usability of the scaffold system for the local release of antibiotics. A respected manufacturer of collagen-based medical devices was won as an application partner.The transfer project is based on solid preparatory work and a large number of publications that have resulted from the work in the SFB/TR 79

原位组织工程（TE）的概念可以开辟新的治疗选择，例如广泛或不愈合的骨缺损。与传统的TE相比，没有细胞被植入，因此这种植入物的成本和批准工作更低。目前的转让项目建立在已完成的SFB/Transregio 79的子项目M4（建立新方法“骨缺损愈合原位组织工程支架”）的工作基础上，并将进一步发展那里与应用合作伙伴一起研究的概念，供临床使用。在TR 79结束时，已经开发了由矿化胶原制成的仿生骨替代材料，其在中央仓库中装载有化学吸引物质。可以证明，在水环境中建立的浓度梯度刺激间充质干细胞和内皮细胞迁移到支架中，因此与未修饰的支架相比，促进了缺损愈合。转移项目的重点现在是（1）将支架生产转移到临床批准的马胶原蛋白，并开发工业上可行的工艺链，（2）为了扩大含药植入物的应用范围，研究用于控制药物释放的替代贮库组分，（3）探索引入药物贮库的新的、合适的策略，（4）研究含药物存款的植入物的可灭菌性和保存期，（5）从低氧条件培养基生产化学吸引药物混合物的标准化和（6）测试支架系统用于抗生素局部释放的可用性。一家受人尊敬的胶原基医疗器械制造商被选为申请合作伙伴。该转移项目基于扎实的准备工作和SFB/TR 79工作产生的大量出版物